Neurology News

Prilenia Therapeutics announced the completion of its global phase 3 study of pridopidine for Huntington’s disease, with topline results expected in the next few months.

Steroid use for at least 10 days before surgery was significantly associated with infectious and noninfectious complications, hospital readmissions and mortality in patients undergoing craniotomy for brain tumors, according to research.

Medical organizations are sounding the alarm after a federal judge ruled that it is unconstitutional to require insurers and health plans to cover preventive services recommended by the U.S. Preventive Services Task Force at no cost.

Neuraly has announced that its investigational NLY01 did not meet the primary study endpoint of improvement in motor symptoms in patients with early, untreated Parkinson’s disease.

Treatment with pitolisant demonstrated significant efficacy in reducing excessive daytime sleepiness and cataplexy in children aged 6 years and older, according to research presented in The Lancet Neurology.

Alzheon Inc. has announced positive interim findings from an ongoing phase 2 study evaluating ALZ-801, an investigational disease-modifying treatment for Alzheimer’s disease.

More intensive blood pressure-lowering therapy was linked to reduced risk for recurrent stroke and major cardiovascular events in patients with stroke or transient ischemic attack, according to research in JAMA Neurology.

Among older patients with atrial fibrillation and dementia, apixaban was associated with lower risk for stroke and major bleeding vs. dabigatran, rivaroxaban or warfarin, researchers reported.

Delandistrogene moxeparvovec improved motor function and was well-tolerated 4 years after treatment in a small cohort of children with Duchenne muscular dystrophy, according to a poster at the 2023 MDA Clinical & Scientific Conference.

Viltolarsen delayed disease progression over 4 years in children with Duchenne muscular dystrophy, with most treatment-emergent adverse events being mild or moderate, according to a poster at the 2023 MDA Clinical & Scientific Conference.